Markets:

Overview

News

Currencies

International

Treasuries

Merck & Co (NY:MRK)

127.50 -0.13 (-0.10%)

Official Closing Price Updated: 7:00 PM EDT, Jul 17, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Merck & Co

< Previous 1 2

...

23 24 25 26 27 28 29 30 Next >

Merck Announces U.S. FDA has Granted Breakthrough Therapy Designation for V116, the Company’s Investigational 21-Valent Pneumococcal Conjugate Vaccine, for the Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults

April 14, 2022

From Merck & Co., Inc.

Via Business Wire

Merck to Hold First-Quarter 2022 Sales and Earnings Conference Call April 28

April 08, 2022

From Merck & Co., Inc.

Via Business Wire

Merck Investor Event Today Will Highlight Broad and Growing Cardiovascular Portfolio and Pipeline in Areas of Unmet Patient Need

April 05, 2022

From Merck & Co., Inc.

Via Business Wire

Expansion of Elkton, Virginia Manufacturing Facility to Further Increase Merck’s HPV Vaccine Supply and Support Broader and Equitable Access

April 04, 2022

From Merck & Co., Inc.

Via Business Wire

Merck Provides Update on FDA Review of Supplemental Biologics License Application for VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for Use in Infants and Children

April 01, 2022

From Merck & Co., Inc.

Via Business Wire

Merck and Ridgeback to Present Data Demonstrating That Treatment With LAGEVRIO™ (molnupiravir) Was Associated With More Rapid Elimination of Infectious SARS-CoV-2 Than Placebo

April 01, 2022

From Merck & Co., Inc.

Via Business Wire

Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) for Patients With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Tumors in Five Different Types of Cancer

March 25, 2022

From Merck & Co., Inc.

Via Business Wire

Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Bevacizumab, as Treatment for Patients With Persistent, Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1 (CPS ≥1)

March 25, 2022

From Merck & Co., Inc.

Via Business Wire

Merck Announces Retirement of Dr. Roy D. Baynes; Dr. Eliav Barr Appointed Head of Global Clinical Development and Chief Medical Officer

March 23, 2022

From Merck & Co., Inc.

Via Business Wire

Systematic Review and Meta-Analysis of Real-World Observational Studies Provide Additional Evidence of Effectiveness of PREVYMIS™ in Preventing Cytomegalovirus Infection and Disease in Adults Undergoing Allogeneic HCT

March 22, 2022

From Merck & Co., Inc.

Via Business Wire

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Patients With MSI‑H/dMMR Advanced Endometrial Carcinoma, Who Have Disease Progression Following Prior Systemic Therapy in Any Setting and Are Not Candidates for Curative Surgery or Radiation

March 21, 2022

From Merck & Co., Inc.

Via Business Wire

Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Disease-Free Survival (DFS) Versus Placebo as Adjuvant Therapy in Patients With Stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC) Regardless of PD-L1 Expression

March 17, 2022

From Merck & Co., Inc.

Via Business Wire

LYNPARZA® (olaparib) Reduced Risk of Death by 32% in Patients With Germline BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer in Phase 3 OlympiA Trial

March 16, 2022

From Merck & Co., Inc.

Via Business Wire

Merck Announces KEYLYNK-010 Trial Evaluating KEYTRUDA® (pembrolizumab) in Combination with LYNPARZA® (olaparib) in Patients with Metastatic Castration-Resistant Prostate Cancer to Stop for Futility

March 15, 2022

From Merck & Co., Inc.

Via Business Wire

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Approved in Japan for Radically Unresectable or Metastatic Renal Cell Carcinoma

February 25, 2022

From Merck & Co., Inc.

Via Business Wire

Merck Shares Environmental, Social & Governance Priorities and Strategy

February 23, 2022

From Merck & Co., Inc.

Via Business Wire

Merck to Hold Event to Discuss Long-Term Environmental, Social & Governance Priorities

February 17, 2022

SOURCE: Merck & Co., Inc.

Via 3BL Media

Merck Announces New Leadership for Human Health Business

February 16, 2022

From Merck & Co., Inc.

Via Business Wire

LYNPARZA® (olaparib) Plus Abiraterone Reduced Risk of Disease Progression or Death by 34% Versus Abiraterone in First-Line Metastatic Castration-Resistant Prostate Cancer, Regardless of Biomarker Status

February 14, 2022

From Merck & Co., Inc.

Via Business Wire

Merck to Hold Event to Discuss Long-Term Environmental, Social & Governance Priorities

February 14, 2022

From Merck & Co., Inc.

Via Business Wire

Merck to Participate in the 11th Annual SVB Leerink Global Healthcare Conference

February 10, 2022

From Merck & Co., Inc.

Via Business Wire

Pivotal Phase 3 Data for KEYTRUDA® (pembrolizumab) in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC) Published in the New England Journal of Medicine

February 09, 2022

From Merck & Co., Inc.

Via Business Wire

Merck and Ridgeback Announce That 3.1 Million Courses of Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine, Have Been Supplied to the U.S. Government for Use in the United States

February 08, 2022

From Merck & Co., Inc.

Via Business Wire

Merck to Participate in the Guggenheim Oncology Conference 2022

February 04, 2022

From Merck & Co., Inc.

Via Business Wire

Merck Announces Fourth-Quarter and Full-Year 2021 Financial Results

February 03, 2022

From Merck & Co., Inc.

Via Business Wire

Merck and Ridgeback’s Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine, Demonstrated Activity Against Omicron Variant in In Vitro Studies

January 28, 2022

From Merck & Co., Inc.

Via Business Wire

European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (RCC) Following Surgery

January 27, 2022

From Merck & Co., Inc.

Via Business Wire

R&D Spending Increases Exponentially for Higher Standard of Breast Cancer Drug Treatments

January 27, 2022

Palm Beach, FL – January 27, 2022 – FinancialNewsMedia.com News Commentary – According to International Agency for Research on Cancer (IARC) published by the World Health Organization (WHO) in 2018,...

Via FinancialNewsMedia

Topics Death Intellectual Property

Merck Announces Second-Quarter 2022 Dividend

January 25, 2022

From Merck & Co., Inc.

Via Business Wire

Merck Provides U.S. and Japan Regulatory Update for Gefapixant

January 24, 2022

From Merck & Co., Inc.

Via Business Wire

< Previous 1 2

...

23 24 25 26 27 28 29 30 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.